FOLH1 and neoplasm: Preliminary data imply that clinically relevant anti-tumor activity is most likely observed in patients with > onefold parotid uptake in the majority of lesions (approx. SUV > 10), and only such patients should actively be encouraged to receive PSMA-RLT [90]; for patients with low PSMA uptake or negative sites, alternative options should be prioritized.